Advances in the selection of therapeutic modalities for BCLC stage-B hepatocellular carcinoma based on enhanced CT radiomics model

doi:10.3969/j.issn.1009-976X.2021.02.022

Abstract

Abstract: Radiomics is a new field by mining high-throughput characteristic data from different medical images, screening potential markers that can reflect the heterogeneity of hepatocellular carcinoma and establishing corresponding models are helpful to the risk stratification,treatment response evaluation and prognosis prediction of BCLC stage-B （intermediate-stage） hepatocellular carcinoma,assist clinical decision-making, provide individualized treatment for patients with BCLC stage-B hepatocellular carcinoma, improve the survival rate and cure rate. This paper reviews the management strategy of BCLC stage-B hepatocellular carcinoma and the application of radiomics in hepatocellular carcinoma, then further discusses the great potential of radiomics model based on enhanced CT in the choice of treatment for BCLC stage-B hepatocellular carcinoma.

Key words: radiomics, BCLC stage-B hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, risk stratification, selection of therapeutic modalities

摘要： 影像组学是一个新兴的领域,通过从不同的医疗图像中挖掘高通量的特征数据筛选能够反映肝癌异质性的标记物并建立相应的模型有助于BCLC B期（中期）肝癌的风险分层、治疗反应评估、预后预测,有助于辅助临床决策,为BCLC B期肝癌患者提供个体化治疗方案,提高生存率和治愈率。本文通过对BCLC B期肝癌的管理策略、影像组学在肝癌中的应用进行综述,进一步探讨了基于增强CT的影像组学模型在对BCLC B期肝细胞癌治疗方式选择中的巨大潜力。

关键词: 影像组学, BCLC B期肝细胞癌, 中期肝癌, 风险分层, 治疗选择

CLC Number:

HU Zhi-peng, SUN Qiang, HU Ze-min, CHEN Wei-qiang. Advances in the selection of therapeutic modalities for BCLC stage-B hepatocellular carcinoma based on enhanced CT radiomics model[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 233-238.

胡志鹏, 孙强, 胡泽民, 陈伟强. 基于增强CT的影像组学模型对BCLC B期肝细胞癌治疗方式选择的研究进展[J]. 岭南现代临床外科, 2021, 21(02): 233-238.

References

[1] Villanueva A.Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
[2] Losic B, Craig AJ, Villacorta-Martin C, et al.Intratumoral heterogeneity and clonal evolution in liver cancer[J]. Nat Commun, 2020, 11(1):291.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
[4] Marrero JA, Kulik LM, Sirlin CB, et al.Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2):723-750.
[5] Lin CT, Hsu KF, Chen TW, et al.Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?[J]. World J Surg, 2010, 34(9):2155-2161.
[6] Zhao YN, Zhang YQ, Ye JZ, et al.Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma[J]. Exp Ther Med, 2016, 12(6):3813-3819.
[7] Cabibbo G, Enea M, Attanasio M, et al.A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma[J]. Hepatology, 2010, 51(4):1274-1283.
[8] Giannini EG, Farinati F, Ciccarese F, et al.Prognosis of untreated hepatocellular carcinoma[J]. Hepatology, 2015, 61(1):184-190.
[9] Giannini EG, Moscatelli A, Pellegatta G, et al.Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma[J]. Am J Gastroenterol, 2016, 111(1):70-77.
[10] Yang B, Zheng B, Yang M, et al.Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma[J]. Hepatol Int, 2018, 12(5):417-428.
[11] Wada H, Eguchi H, Noda T, et al.Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma[J]. Surgery, 2016, 160(5):1227-1235.
[12] Yin L, Li H, Li AJ, et al.Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol, 2014, 61(1):82-88.
[13] Llovet JM, Real MI, Montana X, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319):1734-1739.
[14] Lo CM, Ngan H, Tso WK, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5):1164-1171.
[15] Yang F, Wang Y, Li Q, et al.Intratumor heterogeneity predicts metastasis of triple-negative breast cancer[J]. Carcinogenesis, 2017, 38(9):900-909.
[16] Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution[J]. Nature, 2013, 501(7467):338-345.
[17] Liu J, Dang H, Wang XW.The significance of intertumor and intratumor heterogeneity in liver cancer[J]. Exp Mol Med, 2018, 50(1):e416.
[18] Morris LG, Riaz N, Desrichard A, et al.Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival[J]. Oncotarget, 2016, 7(9):10051-10063.
[19] Ji GW, Zhu FP, Xu Q, et al.Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study[J]. Radiology, 2020;294(3):568-579. doi:10.1148/radiol.2020191470
[20] Sagir Kahraman A.Radiomics in Hepatocellular Carcinoma[J].J Gastrointest Cancer, 2020, 51(4):1165-1168.
[21] Wu W, Parmar C, Grossmann P, et al.Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology[J].Front Oncol, 2016, 6:71.
[22] Yoon HJ, Sohn I, Cho JH, et al.Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach[J]. Medicine (Baltimore), 2015, 94(41):e1753.
[23] Nie K, Shi L, Chen Q, et al.Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI[J]. Clin Cancer Res, 2016, 22(21):5256-5264.
[24] Li H, Zhu Y, Burnside ES, et al.MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays[J]. Radiology, 2016, 281(2):382-391.
[25] Huang YQ, Liang CH, He L, et al.Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer[J]. J Clin Oncol, 2016, 34(18):2157-2164.
[26] Coroller TP, Grossmann P, Hou Y, et al.CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma[J]. Radiother Oncol, 2015, 114(3):345-350.
[27] Parmar C, Grossmann P, Rietveld D, et al.Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer[J]. Front Oncol, 2015, 5:272.
[28] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J].中华肝脏病杂志,2020,28(2):112-128.
[29] Mokrane FZ, Lu L, Vavasseur A, et al.Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules[J]. Eur Radiol, 2020, 30(1):558-570.
[30] Raman SP, Schroeder JL, Huang P, et al.Preliminary data using computed tomography texture analysis for the classification of hypervascular liver lesions: generation of a predictive model on the basis of quantitative spatial frequency measurements--a work in progress[J]. J Comput Assist Tomogr, 2015, 39(3):383-395.
[31] Nie P, Yang G, Guo J, et al.A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver[J]. Cancer Imaging, 2020, 20(1):20.
[32] Xu X, Zhang HL, Liu QP, et al.Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma[J]. J Hepatol,2019, 70(6):1133-1144.
[33] Zheng J, Chakraborty J, Chapman WC, et al. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis [J]. J Am Coll Surg, 2017, 225(6):778-788. e1.
[34] Banerjee S, Wang DS, Kim HJ, et al.A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma[J]. Hepatology, 2015, 62(3):792-800.
[35] Akai H, Yasaka K, Kunimatsu A, et al.Predicting prognosis of resected hepatocellular carcinoma by radiomics analysis with random survival forest[J]. Diagn Interv Imaging, 2018, 99(10):643-651.
[36] Zhou Y, He L, Huang Y, et al.CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma[J]. Abdom Radiol (NY), 2017, 42(6):1695-1704.
[37] Chen S, Zhu Y, Liu Z, Liang C.Texture analysis of baseline multiphasic hepatic computed tomography images for the prognosis of single hepatocellular carcinoma after hepatectomy: A retrospective pilot study[J]. Eur J Radiol, 2017, 90:198-204.
[38] Li M, Fu S, Zhu Y, et al.Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma[J]. Oncotarget, 2016, 7(11):13248-13259.
[39] Reimer RP, Reimer P, Mahnken AH.Assessment of therapy response to transarterial radioembolization for liver metastases by means of post-treatment MRI-based texture analysis[J]. Cardiovasc Intervent Radiol, 2018,41(10):1545-1556.
[40] Kim J, Choi SJ, Lee SH, et al.Predicting survival using pretreatment ct for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics[J]. AJR Am J Roentgenol, 2018, 211(5):1026-1034.